Cortexolone 17α-Propionate (Clascoterone) Is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro

February 2019 in “ PubMed ”

Caridad Rosette, Niccolette Rosette, Alessandro Mazzetti, Luigi Moro, Mara Gerloni

Cortexolone 17α-propionate clascoterone androgen receptor antagonist androgenetic alopecia AGA 5α-reductase inhibitor finasteride enzalutamide IL-6 dihydrotestosterone DHT dermal papilla cells

TLDR Clascoterone may be an effective topical treatment for hair loss.

The study from 2019 investigated the effects of Cortexolone 17α-propionate (clascoterone), a novel androgen antagonist, on androgenetic alopecia (AGA), a hair disorder dependent on androgens. The research found that clascoterone inhibits androgen receptor-regulated transcription similarly to the 5α-reductase inhibitor, finasteride. Moreover, clascoterone was significantly more effective than another direct androgen receptor antagonist, enzalutamide, at inhibiting IL-6 synthesis from dihydrotestosterone-stimulated primary cultures of human scalp dermal papilla cells. These findings suggest that clascoterone could be a promising candidate for the first topical antiandrogen treatment for AGA.

View this study on pubmed.ncbi.nlm.nih.gov →

Discuss this study in the Community →

Related Community Posts Join

6 / 6 results

community Most Recent Interesting Hairloss Studies: 10% Minox vs 5% Minox / Radio Rrequency Treatment for AA / Topical Ketoconazole / PRP+Minox vs Minox vs PRP / Alopecia as a systemic disease

in Treatment 88 upvotes 4 years ago

Treatments for hair loss, such as topical minoxidil, platelet-rich plasma therapy with or without minoxidil, ketoconazole, non-abative radio frequency, natural products, finasteride and cortexolone 17 alpha propionate. The post evaluates the efficacy and safety of these treatments in various studies.

community The New, Improved CB-03-01/Setipiprant Group Buy

27 upvotes 8 years ago

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

community 2020 Hair and Scalp Treatments: A Clinical Guide (in Depth 350 Page Guide)

in Treatment 64 upvotes 4 years ago

Treatments for hair loss, including topical immunotherapy, regenerative treatments, laser and light-based therapies, oral supplements, intralesional steroids, and new drugs like finasteride and minoxidil.

community PYRILUTAMIDE KX-826 experience

in Research/Science 98 upvotes 2 years ago

A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

community Clinical Trial: Clascoterone (Cortexolone 17A-Propionate)

in Research/Science 24 upvotes 8 months ago

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

community Breezula will hit the market in 2026, Cosmo Pharmaceuticals statement!

in Product 52 upvotes 9 months ago

Breezula, a hair loss treatment, is expected to cost around $100 a month and is anticipated to be released in 2026. The effectiveness of Breezula is debated, with some suggesting it loses effectiveness over time and others arguing it maintains hair compared to baseline.

Related Research

1 / 1 results

research Cortexolone 17α-Propionate (Clascoterone) Is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro

4 citations, February 2019 in “PubMed”

Clascoterone may be an effective topical treatment for hair loss.